Download Free Targeted Therapies In Lung Cancer Management Strategies For Nurses And Practitioners Book in PDF and EPUB Free Download. You can read online Targeted Therapies In Lung Cancer Management Strategies For Nurses And Practitioners and write the review.

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer. - Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options - Discusses novel targets and pathways involved in TNBC - Provides insights and approaches for future research on TNBC
From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.
Rising health care costs are a central fiscal challenge confronting the United States. National spending on health care currently accounts for 18 percent of gross domestic product (GDP), but is anticipated to increase to 25 percent of GDP by 2037. The Bipartisan Policy Center argues that "this rapid growth in health expenditures creates an unsustainable burden on America's economy, with far-reaching consequences". These consequences include crowding out many national priorities, including investments in education, infrastructure, and research; stagnation of employee wages; and decreased international competitiveness.In spite of health care costs that far exceed those of other countries, health outcomes in the United States are not considerably better. With the goal of ensuring that patients have access to high-quality, affordable cancer care, the Institute of Medicine's (IOM's) National Cancer Policy Forum convened a public workshop, Delivering Affordable Cancer Care in the 21st Century, October 8-9, 2012, in Washington, DC. Delivering Affordable Cancer Care in the 21st Century summarizes the workshop.
This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
This volume, developed by the Observatory together with OECD, provides an overall conceptual framework for understanding and applying strategies aimed at improving quality of care. Crucially, it summarizes available evidence on different quality strategies and provides recommendations for their implementation. This book is intended to help policy-makers to understand concepts of quality and to support them to evaluate single strategies and combinations of strategies.
Access comprehensive, multidisciplinary guidance on the diagnosis and treatment of lung cancer! This new resource addresses the full range of clinical issues in diagnosis, staging, and treatment, as well as the latest scientific data and evidence-based guidelines. A user-friendlyorganization provides quick reference to data summaries, as well as more comprehensive and detailed information for readers who wish to explore topics in depth. Features contributions by authors from many different disciplines, to ensure a balanced approach. Addresses the clinical issues seen in practice, with the inclusion of basic science research topics that are likely to be put into clinical practice soon. Integrates evidence-based medicine throughout. Assesses the strength of all available dataenabling readers to weigh different arguments and make decisions based on medical issues, values, and the availability and efficacy of interventionsusing a data rating system. Addresses difficult, but clinically relevant issues for which limited data is available. Enables readers to quickly reference findings and data in data summary statements and summary tables.
Modern Thoracic Oncology is the first comprehensive publication on thoracic oncology. Contributors who are world experts have authored concise, relevant and current topics in this field. Whether one desires information regarding lung cancer screening, esophageal cancer staging, mutational analysis, targeted therapies, stereotactic ablative radiation with real-time imaging, minimally-invasive and robotic surgery, combination immunotherapy, microwave/cryoablation, or methods of early cancer detection, this set of three volumes, encompass all of the latest information in the field of thoracic oncology. A rapidly advancing knowledgebase has led to dramatic improvements in individualized or 'personalized' care of patients. However, the myriad of rapid changes has also made it more challenging for thoracic oncologists to comprehend and incorporate these improvements into their daily practice. This staggering and rapid change requires a comprehensive thoracic oncology publication designed to keep clinicians, including pulmonologists, pathologists, radiologists, surgeons, medical oncologists, radiation oncologists and gastroenterologists, well-informed and up-to-date. To meet such needs and to ensure that all areas of thoracic oncology are covered indepth, Modern Thoracic Oncology is published in three volumes.Volume 1 entitled General Principles of Thoracic Oncology provides a comprehensive introduction to thoracic oncology. Principles of thoracic oncology care are discussed in detail and include topics such as thoracic anatomy and embryology, medical evaluation of cancer patients, appropriate imaging modalities with a specific discussion of lung cancer screening, and the basic principles underlying the various treatment modalities. Volume 2 entitled Trachea, Lung, and Pleura addresses lung cancer, one of the most common and deadliest malignancies in the world, as well as two relatively rare respiratory tumors. Volume 3 entitled Esophagus, Mediastinum, Chest Wall and Diaphragm covers esophageal cancer, one of the most rapidly growing malignancies in the world and which still poses significant challenges to thoracic oncologists. Esophageal squamous cell tumors are discussed by experts from Asia where this disease is endemic and adenocarcinoma of the esophagus is detailed by oncologists in the West who face this challenge on a daily basis.